Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates …

Summary This International Myeloma Working Group consensus updates the disease
definition of multiple myeloma to include validated biomarkers in addition to existing …

Background Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–
directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or …

Background G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …

Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …

PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …

Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …

Background Despite recent progress, multiple myeloma remains incurable. Mezigdomide is
a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal …

Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with
pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory …

Background In a phase 1b study, intravenous daratumumab plus pomalidomide and
dexamethasone induced a very good partial response or better rate of 42% and was well …